Ken Griffin Celularity Inc Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.17 - $0.33 $8,467 - $16,436
49,807 New
49,807 $12,000
Q2 2023

Aug 14, 2023
BUY
$0.42 - $0.81 $7,046 - $13,590
16,778 New
16,778 $8,000
Q4 2022

Feb 14, 2023
BUY
$1.08 - $2.35 $40,188 - $87,448
37,212 New
37,212 $48,000

Others Institutions Holding CELU

# of Institutions
3
Shares Held
23.6M
Call Options Held
0
Put Options Held
0
View Full List

About Celularity Inc

CELU Quotes by TradingView
  • Ticker CELU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,424,000
  • Market Cap $329M
  • Description
  • Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-de...
More about CELU
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email